romosozumab

Home
Ligands
romosozumab

GtoPdb Ligand ID: 8092

Synonyms: AMG-785 | CDP-7851 | Evenity® | romosozumab-aqqg

romosozumab is an approved drug (Japan, FDA and EMA (2019))

Comment: Romosozumab is a humanised anti-sclerostin monoclonal antibody that was developed by Amgen and UCB for the treatment of osteoporosis [4-5]. Amgen holds patent protection claiming the polypeptide composition of romosozumab in the US and the EU (expected expiry in 2026).

References
1. Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S, Krumlauf R. (2006) Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res, 21 (11): 1738-49. [PMID:17002572]
2. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R et al.. (2009) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res, 24 (4): 578-88. [PMID:19049336]
3. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D. (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem, 280 (20): 19883-7. [PMID:15778503]
4. Markham A. (2019) Romosozumab: First Global Approval. Drugs, 79 (4): 471-476. [PMID:30805895]
5. McClung MR. (2018) Romosozumab for the treatment of osteoporosis. Osteoporos Sarcopenia, 4 (1): 11-15. [PMID:30775535]
6. Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y, Cao J, Graham K et al.. (2010) Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res, 25 (5): 948-59. [PMID:20200929]
7. Paszty K, Robinson MK, Graham K, Henry AJ, Hoffmann KS, Latham J, Lu HS, Lawson A, Popplewell A, Shen W. (2009) Sclerostin-binding antibody. Patent number: US7592429. Assignee: Ucb Sa, Amgen Inc.. Priority date: 03/05/2005. Publication date: 22/09/2009.

References

1. Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S, Krumlauf R. (2006)
Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
J Bone Miner Res, 21 (11): 1738-49. [PMID:17002572]

2. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R et al.. (2009)
Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
J Bone Miner Res, 24 (4): 578-88. [PMID:19049336]

3. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D. (2005)
Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.
J Biol Chem, 280 (20): 19883-7. [PMID:15778503]

4. Markham A. (2019)
Romosozumab: First Global Approval.
Drugs, 79 (4): 471-476. [PMID:30805895]

5. McClung MR. (2018)
Romosozumab for the treatment of osteoporosis.
Osteoporos Sarcopenia, 4 (1): 11-15. [PMID:30775535]

6. Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y, Cao J, Graham K et al.. (2010)
Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength.
J Bone Miner Res, 25 (5): 948-59. [PMID:20200929]

7. Paszty K, Robinson MK, Graham K, Henry AJ, Hoffmann KS, Latham J, Lu HS, Lawson A, Popplewell A, Shen W. (2009)
Sclerostin-binding antibody.
Patent number: US7592429. Assignee: Ucb Sa, Amgen Inc.. Priority date: 03/05/2005. Publication date: 22/09/2009.